Anabel Jose
Overview
Explore the profile of Anabel Jose including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martinez-Bosch N, Guerrero P, Moreno M, Jose A, Iglesias M, Munne-Collado J, et al.
Oncotarget
. 2016 Jul;
7(30):48265-48279.
PMID: 27374084
Current treatments for pancreatic ductal adenocarcinoma (PDA) are ineffective, making this the 4th leading cause of cancer deaths. Sunitinib is a broad-spectrum inhibitor of tyrosine kinase receptors mostly known for...
2.
Maliandi M, Mato-Berciano A, Sobrevals L, Roue G, Jose A, Fillat C
Mol Cancer
. 2015 Aug;
14:146.
PMID: 26227809
Background: Combined treatment of oncolytic adenoviruses with chemotherapeutic agents is foreseen as a therapeutic option for cancer. Here we have investigated the potential to use gemcitabine in combination with the...
3.
Jose A, Rovira-Rigau M, Luna J, Gimenez-Alejandre M, Vaquero E, Garcia de la Torre B, et al.
J Control Release
. 2014 Jul;
192:148-56.
PMID: 25037019
Selective tumor targeting of oncolytic adenovirus at the level of cell entry remains a major challenge to improve efficacy and safety. Matrix metalloproteases (MMPs) are overexpressed in a variety of...
4.
Fillat C, Jose A, Bofill-Deros X, Mato-Berciano A, Maliandi M, Sobrevals L
Cancers (Basel)
. 2013 Nov;
3(1):368-95.
PMID: 24212620
The continuous identification of molecular changes deregulating critical pathways in pancreatic tumor cells provides us with a large number of novel candidates to engineer gene-targeted approaches for pancreatic cancer treatment....
5.
Jose A, Sobrevals L, Camacho-Sanchez J, Huch M, Andreu N, Ayuso E, et al.
Oncotarget
. 2013 Jan;
4(1):94-105.
PMID: 23328228
Gene-based anticancer therapies delivered by adenoviruses are limited by the poor viral distribution into the tumor. In the current work we have explored the feasibility of targeting pancreatic tumors through...
6.
Boj S, van Es J, Huch M, Li V, Jose A, Hatzis P, et al.
Cell
. 2012 Dec;
151(7):1595-607.
PMID: 23260145
Most studies on TCF7L2 SNP variants in the pathogenesis of type 2 diabetes (T2D) focus on a role of the encoded transcription factor TCF4 in β cells. Here, a mouse...
7.
Jose A, Sobrevals L, Ivorra A, Fillat C
Cancer Lett
. 2011 Nov;
317(1):16-23.
PMID: 22079741
Pancreatic ductal adenocarcinoma (PDAC) therapies show limited success. Irreversible electroporation (IRE) is an innovative loco-regional therapy in which high-voltage pulses are applied to induce plasma membrane defects leading to cellular...
8.
Huch M, Gros A, Jose A, Gonzalez J, Alemany R, Fillat C
Neoplasia
. 2009 Jun;
11(6):518-28, 4 p following 528.
PMID: 19484141
Treatment options for pancreatic cancer have shown limited success mainly owing to poor selectivity for pancreatic tumor tissue and to a lack of activity in the tumor. In this study,...
9.
Pujal J, Huch M, Jose A, Abasolo I, Rodolosse A, Duch A, et al.
FASEB J
. 2009 Jan;
23(5):1366-75.
PMID: 19124560
Keratin 7 is expressed in simple epithelia but is expressed at low or undetectable levels in gastrointestinal epithelial cells. In the pancreas, it is present in ductal but not in...